Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (401-410 of 434) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.
The New England Journal of Medicine|December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and TeclistamabShaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
Cancer|September 23, 2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaPashna N Munshi, David Vesole, Artur Jurczyszyn, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Anita D'Souza, Emma Scott, et al.
Nature Communications|July 23, 2015
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2018
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between GroupsEmma C Scott, Parameswaran Hari, Sathish Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Pageof 44

Showing results (401-410 of 434) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.
The New England Journal of Medicine|December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and TeclistamabShaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
Cancer|September 23, 2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaPashna N Munshi, David Vesole, Artur Jurczyszyn, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Anita D'Souza, Emma Scott, et al.
Nature Communications|July 23, 2015
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2018
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between GroupsEmma C Scott, Parameswaran Hari, Sathish Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Pageof 44